Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Catherine Royer


Catherine Royer has joined Rensselaer Polytechnic Institute as a chair of the school's biocomputation and bioinformatics department, and as a professor in the biology department. She will begin her new roles there this month.

Royer, a molecular biophysicist, is currently director of the Center for Structural Biochemistry in Montpellier, France, a position she has held since 2007. Before that, she was a visiting director of research at the center. Her research focuses on the physical mechanisms through which biological molecules work. She is particularly interested in the mechanisms at play as DNA is transcribed into messenger RNA – with special attention to a group of transcription factors called nuclear receptors – and in the folding of proteins that have been synthesized by the ribosome.

She earned her doctorate in biochemistry at the University of Illinois, Urbana-Champaign, and received a license in biochemistry and a general academic studies degree in natural sciences from the Pierre and Marie Curie University.

Filed under

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.